IN8bio (NASDAQ: INAB)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.380 | -0.0900 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of IN8bio (NASDAQ: INAB) through any online brokerage.
Other companies in IN8bio’s space includes: Vincerx Pharma (NASDAQ:VINC), Aeglea BioTherapeutics (NASDAQ:AGLE), Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB) and Brooklyn (NASDAQ:BTX).
The latest price target for IN8bio (NASDAQ: INAB) was reported by B. Riley Securities on Monday, January 24, 2022. The analyst firm set a price target for 9.00 expecting INAB to rise to within 12 months (a possible 354.55% upside). 3 analyst firms have reported ratings in the last year.
The stock price for IN8bio (NASDAQ: INAB) is $1.98 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for IN8bio.
IN8bio’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for IN8bio.
IN8bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.